Journal of Clinical Trials
Open Access
ISSN: 2167-0870
+44 1478 350008
ISSN: 2167-0870
+44 1478 350008
Ahmed Abdelfattah Mohammed Shoreit, Mohammad Hassan A Hassan, Mady Ahmed Ismail and Ahmad Mohammad Moharram
Assiut University, Egypt
Posters & Accepted Abstracts: J Clin Trials
The aim of this study was to biosynthesize silver nanoparticles (AgNPs) from Staphylococcus arlettae AUMC b-163 isolated from T3A pharmaceutical company clean room, its antimicrobial activity, and the synergistic effect of AgNPs in combination with commonly used antibiotic Cefotaxime sodium against resistant bacteria. The synthesized AgNPs from bacterial were characterized by using UV-VS spectrophotometer analysis, Fourier Transform Infrared Spectroscopy (FTIR), X-ray diffraction (XRD) and Transmission Electron Microscopy (TEM). UV-VS spectrophotometer analysis showed a peak at 420 nm corresponding to the Plasmon absorbance of silver nanoparticles and FTIR analysis showed the potential biomolecule responsible for the reduction of silver. The structural properties of silver nanoparticles were confirmed using XRD technique, while TEM micrographs revealed that the silver nanoparticles are dispersed and aggregated, and mostly having spherical shape within the size range between 8 and 35 nm. The synthesized silver nanoparticles exhibited a varied growth inhibition activity against the tested pathogenic bacteria. A significant increase in area of growth inhibition was observed when a combination of silver nanoparticles and Cefotaxime antibiotics was applied. The current results revealed that the synthesized silver nanoparticles produced by the bacterial strain Staphylococcus arlettae AUMC b-163 is promising to be used in medical therapy due to their broad spectrum against some pathogenic bacteria, fungi and resistant tested bacteria.
Email: ahmedshoreit@yahoo.com